Amrutanjan Health Care Ltd (AMRUTANJAN) — shareholding pattern, promoter holding, financials and share price
About Amrutanjan Health Care Ltd (AMRUTANJAN)
Amrutanjan Health Care Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as AMRUTANJAN and on the BSE under scrip code 590006. Its ISIN is INE098F01031.
AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women's hygiene, and packaged fruit juice drink. [1]
Amrutanjan Health Care Limited is an India-based consumer healthcare company primarily manufacturing and marketing over-the-counter wellness products across pain management, women’s hygiene, congestion relief and rehydration, supported by in-house fine chemicals capabilities and a legacy brand dating to the early 20th century, operating manufacturing plants near Chennai and a growing national distribution network.
Q3 FY26 and YTD Dec’25 show sustained top-line momentum: Q3 net sales rose about 14.9% year-on-year and YTD net sales grew 11.5%, while YTD PBT expanded nearly 17.8%, indicating profitable growth driven by power brands Amrutanjan and Comfy and improved execution despite mixed performance in beverages and Electro+.
Listed peers in Pharmaceuticals: Hester Biosciences Ltd, Windlas Biotech Ltd, Jagsonpal Pharmaceuticals Ltd, Shukra Pharmaceuticals Ltd, Fredun Pharmaceuticals Ltd, Syncom Formulations (India) Ltd.
Valuation & Returns
10 Jul 2026At ₹540 a share on 10 Jul 2026, Amrutanjan Health Care Ltd (AMRUTANJAN) was valued at a price-to-earnings ratio of 26.96x against an industry P/E of 36.41x and a price-to-book of 4.78x on a book value of ₹112.97 per share as of Mar 2025. Solomo computes return on equity of 17.73% and return on capital employed of 23.75% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 26.96x
- Industry P/E
- 36.41x
- P/B
- 4.78x
- EPS (TTM)
- ₹20.03
- Book value / share
- ₹112.97
- ROE
- 17.73%
- ROCE
- 23.75%
- ROA
- 13.74%
- Debt / equity
- 0.01x
- Dividend yield
- 0.85%
- EBITDA margin
- 16.79%
- 52-week range
- ₹490 – ₹789.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2016In the year ended Mar 2016, Amrutanjan Health Care Ltd (AMRUTANJAN) reported revenue of ₹177 crore, net profit of ₹21 crore and earnings per share of ₹7.05. That compares with revenue of ₹158 crore and net profit of ₹15 crore in Mar 2015. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹150 crore and net profit ₹16 crore (standalone).
| Metric | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 136 | 131 | 134 | 158 | 177 |
| Net profit (₹ cr) | 10 | 10 | 12 | 15 | 21 |
| EPS (₹) | 3.32 | 3.47 | 4.26 | 5.1 | 7.05 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 9.90% | 11.56% | 3.64% | 12.11% |
| Profit growth | 9.52% | 15.17% | -8.88% | 38.12% |
| Stock price CAGR | 10% | -5% | -8% | -24% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 46.52% of Amrutanjan Health Care Ltd (AMRUTANJAN) (unchanged from the previous quarter), foreign institutional investors (FII) hold 2.44% and domestic institutional investors (DII) hold 12.28%. Market capitalisation was ₹1,561 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2002.
Largest disclosed public shareholders in Jun 2026: DSP SMALL CAP FUND 3.8%, CARNELIAN BHARAT AMRITKAAL FUND . 2.98%, ICICI PRUDENTIAL FMCG FUND 2.01%, Investor Education and Protection Fund (IEPF) 1.5%, HUF 1.3%, DIPAK KANAYALAL SHAH 1.12%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 46.52% | - | 2.44% | 12.28% | 53.45% |
| Mar 2026 | 46.52% | - | 2.17% | 12.66% | 53.45% |
| Dec 2025 | 46.52% | - | 2.27% | 13% | 53.45% |
| Sep 2025 | 46.52% | - | 2.38% | 12.9% | 53.45% |
| Jun 2025 | 46.52% | - | 2.41% | 12.7% | 53.44% |
| Mar 2025 | 46.52% | - | 2.3% | 11.41% | 53.44% |
| Dec 2024 | 46.52% | - | 2.3% | 11.12% | 53.44% |
| Sep 2024 | 46.52% | - | 2.34% | 10.6% | 53.44% |